Oral peptide formulations have been the long-running drug-delivery challenge in the field. Most peptides degrade in the gut or fail to cross the intestinal epithelium at therapeutic dose. The successful examples — oral semaglutide, oral Wegovy — depend on salt-permeation enhancers like SNAC.
Programmes covered on this site: oral semaglutide and oral Wegovy, Vivtex's permeability platforms, Biocon's oral insulin work, Boehringer's gut-targeted peptide formulations, and the small-molecule oral GLP-1 alternatives (Foundayo / orforglipron) that sidestep the peptide-stability problem altogether.
Stories here cover platform readouts and the partnership deals around them. See #oral-peptide for the singular tag and #drug-delivery for broader delivery technology.
In people aged 55 to 80 with mild cognitive impairment or mild dementia due to Alzheimer's, daily PRI-002 at 300 mg or 600 mg did not beat placebo on the CDR-SB scale at week 48, Priavoid said at the CTAD conference in Boston on November 17. The company pointed to trends at week 72, such as 26.7% slower decline on ADAS-Cog13 (p=0.102), but most were not statistically significant. The drug met its safety endpoint. Brain swelling (ARIA-E) occurred in 2% or fewer patients in each group, and small brain bleeds (ARIA-H) in 8% and 11.7% on the two doses versus 5% on placebo, though a safety board stopped close central MRI checks for ARIA after the first 90 patients reached 24 weeks.
Hong Kong-listed Ascletis asked the FDA to begin human testing of ASC36_37o, a tablet pairing its amylin receptor agonist ASC36 with its triple agonist ASC37. In monkeys, the company reported half-lives of up to 200 hours and 96 hours and oral bioavailability above 10% and at least 9.1%. In obese rats, the combination produced about 69% more weight loss than ASC37 alone. A U.S. Phase 1 study of the amylin pill on its own is underway.
argenx will pay $550 million in cash upfront and up to $595 million in development and regulatory milestones for Santa Cruz, California-based Unnatural Products, whose discovery engine designs macrocyclic peptides, small ring-shaped chains of amino acids that can be built to bind disease targets. argenx said in its November 9 announcement that the peptides could support oral or long-acting medicines for immune-mediated diseases alongside its antibody work; the deal is expected to close by the end of 2026.
In the Phase 3 ICONIC-PsA 1 trial (NCT06878404) in adults with active psoriatic arthritis who had not taken a biologic, 58% on once-daily icotrokinra 200 mg reached ACR20 at week 16 vs. 41% on placebo; ACR50 rates were 29% vs. 16% and ACR70 rates 13% vs. 5%, and J&J did not state significance for either. Among patients with enough psoriasis to score, 57% vs. 14% had clear or almost clear skin (nominal p<0.001). J&J announced the late-breaking ACR Convergence 2026 data on November 7; Icotyde, which blocks the IL-23 receptor, is approved in the U.S. for plaque psoriasis but not psoriatic arthritis.
Genentech scientists dosed two series of closely related macrocyclic peptides, which differed mainly in how quickly pancreatic enzymes broke them down, directly into rats' small intestines with and without sodium decanoate (C10), reporting in Molecular Pharmaceutics. C10 protected all the peptides from pancreatic enzymes in a concentration-dependent way in lab tests and raised their absolute bioavailability in rats, and a half-life of about 60 minutes in a pancreatin stability test without C10 was enough for maximal absorption with the enhancer.
Pharmaceutical scientists at the University of Innsbruck in Austria reviewed in Small on October 24, 2026 reverse micelles, tiny droplets with a water-loving core inside an oily shell, as carriers for oral peptide and protein drugs. They argue that newer dry reverse micelles, with internal water below 1%, avoid the instability of older water-rich versions while protecting peptides from digestive enzymes and helping them cross the gut lining. The authors say animal studies show oral bioavailability comparable to or better than other approaches such as hydrophobic ion pairing in selected systems; the paper is a review, not new data.
Verdiva Bio will present two posters at ADA 2026 on its obesity pipeline: VRB-103, a once-weekly oral amylin-receptor-selective analog, and VRB-104, a unimolecular GLP-1 plus amylin co-agonist. The preclinical data extend the amylin and oral-peptide push from a well-funded newer entrant, as the obesity field broadens beyond incretin monotherapy toward amylin-based and oral approaches.
A study from Christian Heinis's lab, published June 1 in Nature Chemical Biology, screened a library of 15,360 random cyclic peptides for the rare ability to cross cell membranes, then refined a lead (Peptide 30, 890.6 daltons) that blocked the intracellular Keap1-Nrf2 interaction in living cells. By engineering lower charge, fewer hydrogen-bond donors, and smaller polar surface area, the approach reaches targets inside cells without starting from a known ligand, a route toward peptide drugs that can be taken orally.
Syneron Bio, a Beijing-based macrocyclic peptide drug discovery company, closed a $150 million Series B led by an international life-science fund with co-leads Decheng Capital and CDH VGC, roughly four months after a $100 million Series A. Investors include a subsidiary of the Abu Dhabi Investment Authority, Qiming Venture Partners, and existing shareholder AstraZeneca, whose 2025 platform partnership carried $75 million upfront and near-term payments plus up to $3.4 billion in milestones. The raise reflects continued investor appetite for macrocyclic and oral peptide platforms, alongside Pinnacle Medicines' $89 million round.
AJMC ran a consumer-grade FAQ on oral peptides covering bioavailability (typically <1% even with optimized formulations), delivery technologies (SNAC for oral semaglutide, liposomal systems, lipidation as in liraglutide and insulin detemir), and the safety distinction between FDA-approved oral peptides and the wave of unverified products. The piece sits alongside the AMA's late-April primer on injectable peptides and STAT, Scientific American, Washington Post, and ABC News coverage from earlier in the year — collectively building the public-facing safety narrative ahead of the July 23–24 PCAC meeting. The FAQ explicitly flags the FDA expert-panel review and the gap between Category 2 removal and FDA approval.
The Drug Discovery Chemistry Oral & Macrocyclic Peptides Summit (April 14-15, San Diego) convenes as 66 cyclic peptide drugs have gained global approval and the field races to solve oral bioavailability. Key advances include Chugai's Luna18 achieving 21-47% oral bioavailability and Merck's macrocyclic PCSK9 inhibitor enlicitide delivering injectable-level results in pill form.
A comprehensive review in Frontiers in Drug Delivery examines the barriers to oral peptide bioavailability — enzymatic degradation, poor membrane permeability, and first-pass metabolism — and maps emerging solutions including permeation enhancers, nanoparticle encapsulation, mucoadhesive systems, and microRNA-based approaches that are advancing toward clinical translation.
OrbiMed-incubated startup revealed $89M in funding to develop oral peptide drugs with biologic-level efficacy. Lead program targets asthma and is on track for clinical trials.
Pinnacle closed an oversubscribed $89M Series B (total $134M) to advance AI-driven oral peptide therapeutics into clinical trials, focusing on immunology and cardiometabolic diseases.